Our case is the first reported case of ocular dirofilariasis from Western India and was managed with adequate surgical excision with conjunctival autograft. This first indigenous, case of ocular dirofilaria from Western India highlights the importance of being aware of this infection for ophthalmologists from this part of the country; this can help in increased recognition and reporting of such infections.

Acknowledgment

The authors wish to thank Dr Madhav Sathe, Dept of Microbiology, Seth G S Medical College, K E M Hospital and Dr Leena Gajbar, Aditya Labs, Panvel for their assistance in microbiological identification of the worm and Dr Maninder Setia, Dept of Clinical research and Epidemiology, Laxmi Eye Institute, Panvel, for editorial comments.

Vishram A Sangit, Suhas S Haldipurkar
Cornea and Uvea Services, Laxmi Eye Institute, Panvel, Raigad, India

Correspondence to:
Dr. Vishram A. Sangit, Cornea and Uvea Services, Laxmi Eye Institute, Old Uran road, Panvel, Raigad – 410 206, Maharashtra, India.
E-mail: vishramsangit@rediffmail.com

References

1. Rani PA, Irwin PJ, Gatne M, Coleman GT, McInnes LM, Traub RJ. A survey of canine filarial diseases of veterinary and public health significance in India. Parasit Vectors 2010;3:30.
2. Nath R, Gogoi R, Bordoloi N, Gogoi T. Ocular Dirofilariasis. Indian J Pathol Microbiol 2010;53:157-9.

Dear Editor,

Diplopia after Botulinum Toxin A (BTX) injection for facial rejuvenation is rare, transient and recurrent with re-injections.\(^1\) It is mostly associated with inferior oblique paresis\(^1\)\(^-\)\(^3\) or rarely with lateral rectus paresis.\(^4\) Here, we report a superior oblique paresis following BTX injection for facial rejuvenation. A literature search on Google and PubMed did not show a report.

A 48-year-old man presented with blurred vision since three weeks that disappeared on tilting the head to the left. Three weeks prior, he had received BTX for facial rejuvenation. Blurred vision was noticed on the next day. It was his sixth treatment with BTX in the last three years. His reports indicated that 48U BTX was administered [Fig. 1]. The injections were given in the sitting position and the brow injection on the
right was allegedly administered ‘too’ close to the eye. There was no history of recent head injury, diabetes, hypertension or hyperlipidemia.

His best corrected distance and near vision was 20/20, N6 in both eyes. Examination of the pupils, anterior segment and posterior segment was normal. The orthoptic examination revealed an abnormal head posture (10 degrees tilt to the left). In forced primary position, there was a right hypertropia of 2Δ that increased to 6Δ in levorversion and 6Δ on right head tilt. Hypertropia disappeared in dextroversion and with left head tilt. Extraocular movements were normal. Hess chart demonstrated mild weakness of the right superior oblique [Fig. 2]. Double Maddox rod test was normal. Neutralization of diplopia in free space confirmed the findings of the cover test. Fundus examination revealed trace extorsion in the right eye and no torsion in the left.

Other cranial nerves functioned normally. Neuroimaging of the brain was advised. However, the patient was lost to follow-up and reported back after one month with normal ocular motility and no diplopia.

BTX-induced chemo-denervation is a minimally invasive, focused, safe and effective therapy for facial rejuvenation.[1] Minute quantities (units) and volume of the drug injected, better anatomical knowledge of the affected muscles and improved techniques have significantly reduced the incidence of complications. Nevertheless, diplopia after BTX for facial rejuvenation occurs in 2.1% patients.[1] In most cases, the pattern of the palsy remains unidentifiable or affects the inferior oblique muscle. BTX-induced superior oblique palsy is not reported.

Typical complaints, pattern of ocular motility disturbances, history of BTX injection prior to the onset of symptoms and the self-limiting nature of the disease in this patient indicate transient superior oblique paresis due to BTX.

Potential risk factors in this patient were inherent susceptibility (causing higher intraorbital diffusion), proximity of the needle tip to the trochlea (faulty technique), deep penetration of the needle into the orbital septum (faulty technique) and increased diffusion of the drug following repeated injections.[3] The clinicians engaged in BTX for facial rejuvenation should inform the patients about the possibility of this potential complication. Adequate technical modifications and/or adjustment in the dose and/or volume may be necessary to avoid this complication, especially with repeated treatments.

Mihir Kothari, Najeeha Shukri, Abdul Quayyum
Department of Pediatric Ophthalmology and Strabismus, Aditya Jyot Eye Hospital, Mumbai, India

Correspondence to: Dr. Mihir Kothari, Jyotirmay Eye Clinic and Pediatric, Low Vision Center, 205, Ganatra Estate, Next to Punjani Ind. Estate, Pokhran Rd. No 1, Thane (W)-400601, Maharashtra, India.
E-mail: drmihirkothari@jyotirmay.com

References
1. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol 2007;52:13-31.
2. Aristodemou P, Watt L, Baldwin C, Hugkulstone C. Diplopia associated with the cosmetic use of botulinum toxin a for facial rejuvenation. Ophth Plast Reconstr Surg 2006;22:134-6.
3. Wutthiphan S, Kowal L, O’Day J, Jones S, Price J. Diplopia following subcutaneous injections of botulinum A toxin for facial spasms. J Pediatr Ophthalmol Strabismus 1997;34:229-34.
4. Chen CS, Miller NR. Botulinum toxin injection causing lateral rectus palsy. Br J Ophthalmol 2007;91:843.

Access this article online
Quick Response Code: Website: www.ijo.in
DOI: 10.4103/0301-4738.90496

---

**Figure 1:** Sketch showing the dose distribution and injection sites of BTX. The potential likely site resulting in superior oblique paresis is marked by a highlighted star

**Figure 2:** Hess chart showing small hypertropia in the right eye associated with ipsilateral superior oblique muscle underaction